Last reviewed · How we verify
Lispro Prandial Insulin
Lispro Prandial Insulin is a Small molecule drug developed by Eli Lilly and Company. It is currently in Phase 1 development.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Eli Lilly and Company is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Lispro Prandial Insulin |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Nasopharyngitis
- Upper respiratory tract infection
- Influenza
- Urinary tract infection
- Dermatitis contact
- Covid-19
- Diarrhoea
- Cough
- Rhinitis
- Headache
- Pyrexia
- Pharyngitis
Key clinical trials
- Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes (NA)
- A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM) (PHASE1)
- DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes (PHASE4)
- The Impact of Two Different Insulin Dose Calculation on Postprandial Glycemia After Mixed Meal. (PHASE4)
- A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy (PHASE3)
- Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD) (PHASE4)
- Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (NA)
- FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lispro Prandial Insulin CI brief — competitive landscape report
- Lispro Prandial Insulin updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI
Frequently asked questions about Lispro Prandial Insulin
What is Lispro Prandial Insulin?
Who makes Lispro Prandial Insulin?
What development phase is Lispro Prandial Insulin in?
What are the side effects of Lispro Prandial Insulin?
Related
- Manufacturer: Eli Lilly and Company — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing